Market closed
Coherus BioSciences/$CHRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Coherus BioSciences
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
Ticker
$CHRS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
228
Website
CHRS Metrics
BasicAdvanced
$119M
4.14
$0.25
0.92
-
Price and volume
Market cap
$119M
Beta
0.92
52-week high
$2.32
52-week low
$0.66
Average daily volume
2M
Financial strength
Current ratio
2.059
Quick ratio
1.412
Long term debt to equity
-200.717
Total debt to equity
-200.717
Interest coverage (TTM)
-3.87%
Management effectiveness
Return on assets (TTM)
-12.17%
Return on equity (TTM)
-17.52%
Valuation
Price to earnings (TTM)
4.139
Price to revenue (TTM)
0.442
Price to book
-0.9
Price to tangible book (TTM)
-0.64
Price to free cash flow (TTM)
-3.582
Growth
Revenue change (TTM)
3.78%
Earnings per share change (TTM)
-109.85%
3-year revenue growth (CAGR)
-6.50%
3-year earnings per share growth (CAGR)
-59.71%
What the Analysts think about CHRS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Coherus BioSciences stock.
CHRS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CHRS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CHRS News
AllArticlesVideos
Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs
Seeking Alpha·1 week ago
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
GlobeNewsWire·2 weeks ago
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Coherus BioSciences stock?
Coherus BioSciences (CHRS) has a market cap of $119M as of April 27, 2025.
What is the P/E ratio for Coherus BioSciences stock?
The price to earnings (P/E) ratio for Coherus BioSciences (CHRS) stock is 4.14 as of April 27, 2025.
Does Coherus BioSciences stock pay dividends?
No, Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders as of April 27, 2025.
When is the next Coherus BioSciences dividend payment date?
Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Coherus BioSciences?
Coherus BioSciences (CHRS) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.